BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32595092)

  • 1. Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence.
    Barbas Bernardos G; Herranz Amo F; González San Segundo C; Caño Velasco J; Subirá Ríos D; Moralejo Gárate M; Mayor de Castro J; Aragón Chamizo J; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):701-707. PubMed ID: 32595092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological control in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy.
    Caño-Velasco J; Herranz-Amo F; Barbas-Bernardos G; Polanco-Pujol L; Verdú-Tartajo F; Lledó-García E; Hernández-Fernández C
    Actas Urol Esp (Engl Ed); 2019 May; 43(4):190-197. PubMed ID: 30878158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
    Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN
    Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
    Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
    Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomy.
    Kashihara T; Nakamura S; Wakita A; Okamoto H; Inaba K; Umezawa R; Shima S; Tsuchida K; Kobayashi K; Takahashi K; Murakami N; Ito Y; Igaki H; Fujimoto H; Uno T; Itami J
    Cancer Med; 2018 May; 7(5):1723-1730. PubMed ID: 29573193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
    Viani GA; Hamamura AC; Correa AC; de Arruda FT
    Int Braz J Urol; 2019; 45(2):237-245. PubMed ID: 30676298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.
    Lohm G; Lütcke J; Jamil B; Höcht S; Neumann K; Hinkelbein W; Wiegel T; Bottke D
    Strahlenther Onkol; 2014 Aug; 190(8):727-31. PubMed ID: 24577132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
    Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
    Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.
    Hugen CM; Polcari AJ; Quek ML; Garza RP; Fitzgerald MP; Flanigan RC
    World J Urol; 2010 Dec; 28(6):741-4. PubMed ID: 20449749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
    Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
    Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
    Bartkowiak D; Thamm R; Siegmann A; Böhmer D; Budach V; Wiegel T
    Radiother Oncol; 2021 Jan; 154():255-259. PubMed ID: 32920006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of biochemical recurrence after radical prostatectomy. New tool for selecting candidates for adjuvant radiation therapy.
    Herranz-Amo F; Molina-Escudero R; Ogaya-Pinies G; Ramírez-Martín D; Verdú-Tartajo F; Hernández-Fernández C
    Actas Urol Esp; 2016 Mar; 40(2):82-7. PubMed ID: 26424411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.